Turlough Montague, James Drummond, Karl Ng, John Parratt
{"title":"Advancements in multiple sclerosis.","authors":"Turlough Montague, James Drummond, Karl Ng, John Parratt","doi":"10.1111/imj.70023","DOIUrl":null,"url":null,"abstract":"<p><p>The global prevalence of multiple sclerosis (MS) is increasing, and early diagnosis and treatment is essential in mitigating disability. While recent therapeutic advancements have significantly reduced relapse rates, the progressive and degenerative aspects of MS continue to pose major challenges. This year updates to the McDonald diagnostic criteria aim to enhance sensitivity and facilitate earlier use of disease-modifying therapies in asymptomatic patients. Additionally, novel biomarkers will gain ground in clinical practice and offer new approaches to optimising care. Following the widespread use of cell depleting immunosuppressive agents, innovative therapeutic directions such as chimeric antigen receptor T-cell therapy and Epstein-Barr virus (EBV) vaccination represent promising new directions in the management of MS. This clinical perspective provides a comprehensive overview of the disease while highlighting important advancements shaping the future of the field.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.70023","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
The global prevalence of multiple sclerosis (MS) is increasing, and early diagnosis and treatment is essential in mitigating disability. While recent therapeutic advancements have significantly reduced relapse rates, the progressive and degenerative aspects of MS continue to pose major challenges. This year updates to the McDonald diagnostic criteria aim to enhance sensitivity and facilitate earlier use of disease-modifying therapies in asymptomatic patients. Additionally, novel biomarkers will gain ground in clinical practice and offer new approaches to optimising care. Following the widespread use of cell depleting immunosuppressive agents, innovative therapeutic directions such as chimeric antigen receptor T-cell therapy and Epstein-Barr virus (EBV) vaccination represent promising new directions in the management of MS. This clinical perspective provides a comprehensive overview of the disease while highlighting important advancements shaping the future of the field.
多发性硬化症（MS）的全球发病率正在上升，早期诊断和治疗对于减轻残疾至关重要。虽然最近的治疗进展大大降低了复发率，但多发性硬化症的进行性和退行性仍是一大挑战。今年对麦克唐纳诊断标准进行了更新，旨在提高敏感性，方便无症状患者更早地使用改变病情的疗法。此外，新型生物标志物也将在临床实践中得到应用，并为优化治疗提供新的方法。继广泛使用细胞损耗免疫抑制剂之后，嵌合抗原受体 T 细胞疗法和 Epstein-Barr 病毒（EBV）疫苗接种等创新治疗方法代表了多发性硬化症治疗的新方向，前景广阔。本临床视角全面概述了这一疾病，同时强调了塑造该领域未来的重要进展。
期刊介绍：
The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
